Ladislav Drož, CEO of APIGENEX, reveals the company’s strategy to survive after a leadership change and a reshuffling of the small-molecule science operations at their main client, Novo Nordisk. Drož also discusses APIGENEX’s future goals of investing in robotics and automation. APIGENEX’s services include chemistry, experimental pharmacology, clinical pharmacology, registration and pharmacovigilance to offer not only MNCs, but also local industry and academia, the opportunity to have their idea become a reality.
In [Novo Nordisk's] own words: “APIGENEX is our VIP CRO in chemistry and pharmacology”
